Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A pediatric oncology group study

J. P. Krischer, A. H. Ragab, L. Kun, T. H. Kim, J. P. Laurent, J. M. Boyett, C. J. Cornell, M. Link, A. R. Luthy, B. Camitta

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

In a randomized postoperative trial, adjuvant post-irradiation chemotherapy, consisting of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP), was tested versus radiation therapy alone for newly diagnosed medulloblastoma in patients between 1 and 21 years of age. Patients treated with irradiation plus MOPP had a statistically significant increase in overall survival rate at 5 years posttreatment compared to patients treated with radiation therapy alone (74% vs. 56%; p = 0.06, adjusted for race and gender). Although the overall study failed to show a statistically significant advantage for irradiation plus MOPP in event-free survival (p = 0.18), statistical significance was attained in children 5 years of age or older (p = 0.05). More severe hematological toxicities occurred in the group with irradiation plus MOPP; however, this hematotoxicity appeared to be tolerable and acceptable. These results suggest that patients may benefit from combined irradiation and chemotherapy following surgery for medulloblastoma.

Original languageEnglish (US)
Pages (from-to)905-909
Number of pages5
JournalJournal of Neurosurgery
Volume74
Issue number6
DOIs
StatePublished - Jan 1 1991

Fingerprint

Procarbazine
Mechlorethamine
Medulloblastoma
Vincristine
Adjuvant Chemotherapy
Prednisone
Pediatrics
Radiotherapy
Drug Therapy
Therapeutics
Disease-Free Survival
Survival Rate

Keywords

  • chemotherapy
  • medulloblastoma
  • outcome
  • radiation therapy

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A pediatric oncology group study. / Krischer, J. P.; Ragab, A. H.; Kun, L.; Kim, T. H.; Laurent, J. P.; Boyett, J. M.; Cornell, C. J.; Link, M.; Luthy, A. R.; Camitta, B.

In: Journal of Neurosurgery, Vol. 74, No. 6, 01.01.1991, p. 905-909.

Research output: Contribution to journalArticle

Krischer, JP, Ragab, AH, Kun, L, Kim, TH, Laurent, JP, Boyett, JM, Cornell, CJ, Link, M, Luthy, AR & Camitta, B 1991, 'Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A pediatric oncology group study', Journal of Neurosurgery, vol. 74, no. 6, pp. 905-909. https://doi.org/10.3171/jns.1991.74.6.0905
Krischer, J. P. ; Ragab, A. H. ; Kun, L. ; Kim, T. H. ; Laurent, J. P. ; Boyett, J. M. ; Cornell, C. J. ; Link, M. ; Luthy, A. R. ; Camitta, B. / Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A pediatric oncology group study. In: Journal of Neurosurgery. 1991 ; Vol. 74, No. 6. pp. 905-909.
@article{f5ae7ababe80467a9933f625918d3ecb,
title = "Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A pediatric oncology group study",
abstract = "In a randomized postoperative trial, adjuvant post-irradiation chemotherapy, consisting of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP), was tested versus radiation therapy alone for newly diagnosed medulloblastoma in patients between 1 and 21 years of age. Patients treated with irradiation plus MOPP had a statistically significant increase in overall survival rate at 5 years posttreatment compared to patients treated with radiation therapy alone (74{\%} vs. 56{\%}; p = 0.06, adjusted for race and gender). Although the overall study failed to show a statistically significant advantage for irradiation plus MOPP in event-free survival (p = 0.18), statistical significance was attained in children 5 years of age or older (p = 0.05). More severe hematological toxicities occurred in the group with irradiation plus MOPP; however, this hematotoxicity appeared to be tolerable and acceptable. These results suggest that patients may benefit from combined irradiation and chemotherapy following surgery for medulloblastoma.",
keywords = "chemotherapy, medulloblastoma, outcome, radiation therapy",
author = "Krischer, {J. P.} and Ragab, {A. H.} and L. Kun and Kim, {T. H.} and Laurent, {J. P.} and Boyett, {J. M.} and Cornell, {C. J.} and M. Link and Luthy, {A. R.} and B. Camitta",
year = "1991",
month = "1",
day = "1",
doi = "10.3171/jns.1991.74.6.0905",
language = "English (US)",
volume = "74",
pages = "905--909",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "6",

}

TY - JOUR

T1 - Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A pediatric oncology group study

AU - Krischer, J. P.

AU - Ragab, A. H.

AU - Kun, L.

AU - Kim, T. H.

AU - Laurent, J. P.

AU - Boyett, J. M.

AU - Cornell, C. J.

AU - Link, M.

AU - Luthy, A. R.

AU - Camitta, B.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - In a randomized postoperative trial, adjuvant post-irradiation chemotherapy, consisting of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP), was tested versus radiation therapy alone for newly diagnosed medulloblastoma in patients between 1 and 21 years of age. Patients treated with irradiation plus MOPP had a statistically significant increase in overall survival rate at 5 years posttreatment compared to patients treated with radiation therapy alone (74% vs. 56%; p = 0.06, adjusted for race and gender). Although the overall study failed to show a statistically significant advantage for irradiation plus MOPP in event-free survival (p = 0.18), statistical significance was attained in children 5 years of age or older (p = 0.05). More severe hematological toxicities occurred in the group with irradiation plus MOPP; however, this hematotoxicity appeared to be tolerable and acceptable. These results suggest that patients may benefit from combined irradiation and chemotherapy following surgery for medulloblastoma.

AB - In a randomized postoperative trial, adjuvant post-irradiation chemotherapy, consisting of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP), was tested versus radiation therapy alone for newly diagnosed medulloblastoma in patients between 1 and 21 years of age. Patients treated with irradiation plus MOPP had a statistically significant increase in overall survival rate at 5 years posttreatment compared to patients treated with radiation therapy alone (74% vs. 56%; p = 0.06, adjusted for race and gender). Although the overall study failed to show a statistically significant advantage for irradiation plus MOPP in event-free survival (p = 0.18), statistical significance was attained in children 5 years of age or older (p = 0.05). More severe hematological toxicities occurred in the group with irradiation plus MOPP; however, this hematotoxicity appeared to be tolerable and acceptable. These results suggest that patients may benefit from combined irradiation and chemotherapy following surgery for medulloblastoma.

KW - chemotherapy

KW - medulloblastoma

KW - outcome

KW - radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0025736863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025736863&partnerID=8YFLogxK

U2 - 10.3171/jns.1991.74.6.0905

DO - 10.3171/jns.1991.74.6.0905

M3 - Article

C2 - 2033450

AN - SCOPUS:0025736863

VL - 74

SP - 905

EP - 909

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 6

ER -